Zobrazeno 1 - 10
of 204
pro vyhledávání: '"Andreas, Viardot"'
Autor:
Max Topp, Monika Dlugosz-Danecka, Aleksander B. Skotnicki, Galina Salogub, Andreas Viardot, Andreas K. Klein, Georg Hess, Christian S. Michel, Sebastian Grosicki, Alex Gural, Sylvia E. Schwarz, Kerstin Pietzko, Ulrike Gärtner, András Strassz, Leila Alland, Jiri Mayer
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Background The prognosis for patients with relapsed and/or refractory (R/R) non-Hodgkin’s lymphoma (NHL) or acute lymphoblastic leukaemia (ALL) remains poor, with existing treatments having significant side effects. Developed for the treat
Externí odkaz:
https://doaj.org/article/733ebcc0ead14adca31fae5c33809819
Autor:
Sascha d’Almeida, Sinisa Markovic, Patrick Hermann, Hendrik Bracht, Johannes Peifer, Thomas J. Ettrich, Armin Imhof, Shaoxia Zhou, Manfred Weiss, Andreas Viardot, Wolfgang Rottbauer, Tillman Dahme
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
Cases of thromboembolic events in 2021 flared up the discussion about the safety of Astra Zeneca’s AZD1222 vaccine. We hereby report three cases of pulmonary embolism (PE), one case of extended portal vein thrombosis, and one case of combined porta
Externí odkaz:
https://doaj.org/article/7c2367bf8b5a4d3892fd1006a3ff0903
Autor:
Fabian Lang, Heike Pfeifer, Simon Raffel, Walter Fiedler, Maher Hanoun, Mathias Hänel, Bernd Spriewald, Andreas Viardot, Vladan Vucinic, Hubert Serve, Dieter Hoelzer, Nicola Gökbuget
Publikováno v:
HemaSphere, Vol 7, p e67660c6 (2023)
Externí odkaz:
https://doaj.org/article/20b8b882bdc74eecb135f2c1234d8edb
Autor:
Heike Pfeifer, Fabian Lang, Walter Fiedler, Matthias Stelljes, Folker Schneller, Björn Steffen, Boris Böll, Andreas Viardot, Christoph Faul, Lino Lars Teichmann, Hendrik Poeck, Jörg Westermann, Kerstin Schaefer-Eckart, Thomas Heinicke, Hubert Serve, Monika Brüggemann, Stefan Schwartz, Thomas Burmeister, Nicola Gökbuget
Publikováno v:
HemaSphere, Vol 7, p e33834d6 (2023)
Externí odkaz:
https://doaj.org/article/d7e30d3856a94e4e818399cb7435ffa3
Autor:
Lorenz Thurner, Marita Ziepert, Christian Berdel, Christian Schmidt, Peter Borchmann, Dominic Kaddu-Mulindwa, Andreas Viardot, Mathias Witzens-Harig, Judith Dierlamm, Mathias Haenel, Bernd Metzner, Gerald Wulf, Eva Lengfelder, Ulrich B. Keller, Norbert Frickhofen, Maike Nickelsen, Tobias Gaska, Frank Griesinger, Rolf Mahlberg, Reinhard Marks, Ofer Shpilberg, Hans-Walter Lindemann, Martin Soekler, Ludwig Fischer von Weikersthal, Michael Kiehl, Eva Roemer, Martin Bentz, Beate Krammer-Steiner, Ralf Trappe, Peter de Nully Brown, Massimo Federico, Francesco Merli, Marianne Engelhard, Bertram Glass, Norbert Schmitz, Lorenz Truemper, Moritz Bewarder, Frank Hartmann, Niels Murawski, Stephan Stilgenbauer, Andreas Rosenwald, Bettina Altmann, Heinz Schmidberger, Jochen Fleckenstein, Markus Loeffler, Viola Poeschel, Gerhard Held, on behalf of German Lymphoma Alliance (GLA)
Publikováno v:
HemaSphere, Vol 7, Iss 7, p e904 (2023)
UNFOLDER (Unfavorable Young Low-Risk Densification of R-Chemo Regimens) is an international phase-3 trial in patients 18–60 years with aggressive B-cell lymphoma and intermediate prognosis defined by age-adjusted International Prognostic Index (aaI
Externí odkaz:
https://doaj.org/article/1e8a36d90cfc4a6ab52a8d26ac285de3
Autor:
Gerhard Held, Lorenz Thurner, Viola Poeschel, German Ott, Christian Schmidt, Konstantinos Christofyllakis, Andreas Viardot, Peter Borchmann, Walburga Engel-Riedel, Norbert Frickhofen, Maike Nickelsen, Ofer Shpilberg, Mathias Witzens-Harig, Frank Griesinger, Beate Krammer-Steiner, Andreas Neubauer, Peter de Nully Brown, Massimo Federico, Bertram Glass, Norbert Schmitz, Gerald Wulf, Lorenz Truemper, Moritz Bewarder, Niels Murawski, Stephan Stilgenbauer, Andreas Rosenwald, Bettina Altmann, Marianne Engelhard, Heinz Schmidberger, Jochen Fleckenstein, Christian Berdel, Markus Loeffler, Marita Ziepert, on behalf of the German Lymphoma Alliance (GLA)
Publikováno v:
HemaSphere, Vol 7, Iss 7, p e917 (2023)
UNFOLDER (NCT00278408, EUDRACT 2005-005218-19) is a phase-3 trial in patients with aggressive B-cell lymphoma and intermediate prognosis, including primary mediastinal B-cell lymphoma (PMBCL). In a 2 × 2 factorial design, patients were randomized to
Externí odkaz:
https://doaj.org/article/f39990c175e24501836e410f27b615d4
Autor:
Stephanie E. Weissinger, Rucha Dugge, Miriam Disch, Thomas F. Barth, Johannes Bloehdorn, Malena Zahn, Ralf Marienfeld, Andreas Viardot, Peter Möller
Publikováno v:
eJHaem, Vol 3, Iss 3, Pp 688-697 (2022)
Abstract Primary extranodal diffuse large B‐cell lymphoma (PE‐DLBCL) is a heterogeneous subgroup of DLBCL. We investigated the prevalence and prognostic value of surface expression of PD‐L1, PD1, and CD30, copy number of 9p24.1 (PD‐L1 region)
Externí odkaz:
https://doaj.org/article/5b94006d842a43458095cdf8d6518307
Autor:
Nicola Gökbuget, Kristina Ihrig, Michael Stadler, Matthias Stelljes, Ahmet Elmaagacli, Michael Starck, Simon Raffel, Andrea Stoltefuss, Andreas Viardot, Karl-Anton Kreuzer, Daniela Heidenreich, Andrea Renzelmann, Ralph Wäsch, Max S. Topp, Barbara Ritter, Peter Reimer, Joachim Beck, Jörg Westermann, Knut Wendelin, Nael Alakel, Maher Hanoun, Hubert Serve, Dieter Hoelzer
Publikováno v:
Haematologica, Vol 108, Iss 7 (2023)
Cure rates in adult acute lymphoblastic leukemia (ALL) improved using pediatric-based chemotherapy and stem cell transplantation (SCT). However, limited data on the health condition of cured adults are available whereas pediatric data cannot be trans
Externí odkaz:
https://doaj.org/article/1d8dab2a15d6455985acc8405cfa5220
Autor:
Friederike Braulke, Florian Zettl, Marita Ziepert, Andreas Viardot, Christoph Kahl, Gabriele Prange-Krex, Agnieszka Korfel, Martin Dreyling, Alexander Bott, Ulrich Wedding, Dietmar Reichert, Maike de Wit, Frank Hartmann, Viola Poeschel, Norbert Schmitz, Mathias Witzens-Harig, Wolfram Klapper, Andreas Rosenwald, Gerald Wulf, Bettina Altmann, Lorenz Trümper
Publikováno v:
HemaSphere, Vol 6, Iss 12, p e808 (2022)
The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we
Externí odkaz:
https://doaj.org/article/454022e1c0504a2caa116000c0379a95
Autor:
Alexander Grunenberg, Lisa M. Kaiser, Stephanie Woelfle, Birgit Schmelzle, Andreas Viardot, Peter Möller, Thomas F. E. Barth, Rainer Muche, Jens Dreyhaupt, Markus Raderer, Barbara Kiesewetter, Christian Buske
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Advanced stage marginal zone lymphoma (MZL) is an incurable indolent B-cell lymphoma, for which a wide variety of treatments ranging from single agent rituximab to more dose intense immunochemotherapy exists. One of the major goal
Externí odkaz:
https://doaj.org/article/85507aa528014e0a88247fc7854da8c9